| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2124580 | European Journal of Cancer | 2009 | 8 Pages |
Abstract
LOH 16q is an adverse risk factor in favourable histology Wilms tumour, regardless of initial approach to therapy. Its relationship with histological risk groups defined after neo-adjuvant chemotherapy requires analysis in a larger series, and is the subject of the current SIOP WT 2001 trial.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Boo Messahel, Richard Williams, Antonia Ridolfi, Roger A'Hern, William Warren, Lorna Tinworth, Rachel Hobson, Reem Al-Saadi, Gavin Whyman, Marie-Anne Brundler, Anna Kelsey, Neil Sebire, Chris Jones, Gordan Vujanic, Kathy Pritchard-Jones,